Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Preferred Stock Liabilities (2019 - 2021)

Historic Preferred Stock Liabilities for P3 Health Partners (PIIIW) over the last 3 years, with Q4 2021 value amounting to $47.0 million.

  • P3 Health Partners' Preferred Stock Liabilities changed N/A to $47.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $47.0 million, marking a year-over-year change of. This contributed to the annual value of $47.0 million for FY2021, which is N/A changed from last year.
  • Per P3 Health Partners' latest filing, its Preferred Stock Liabilities stood at $47.0 million for Q4 2021.
  • In the past 5 years, P3 Health Partners' Preferred Stock Liabilities ranged from a high of $52.7 million in Q1 2021 and a low of $47.0 million during Q2 2021
  • Moreover, its 3-year median value for Preferred Stock Liabilities was $47.3 million (2019), whereas its average is $48.8 million.
  • The largest annual percentage gain for P3 Health Partners' Preferred Stock Liabilities in the last 5 years was 852.1% (2020), contrasted with its biggest fall of 852.1% (2020).
  • Quarter analysis of 3 years shows P3 Health Partners' Preferred Stock Liabilities stood at $47.6 million in 2019, then increased by 8.52% to $51.6 million in 2020, then dropped by 8.85% to $47.0 million in 2021.
  • Its Preferred Stock Liabilities stands at $47.0 million for Q4 2021, versus $47.0 million for Q3 2021 and $47.0 million for Q2 2021.